CA209-9DX: phase III, randomized, double-blind study of adjuvant nivolumab vs placebo for patients with hepatocellular carcinoma (HCC) at high risk of recurrence after curative resection or ablation

被引：0

作者：

Exposito, M. J. Jimenez ^{[1
]}

Akce, M. ^{[2
]}

Montero Alvarez, J. L. ^{[3
]}

Assenat, E. ^{[4
]}

Balart, L. A. ^{[5
]}

Baron, A. D. ^{[6
]}

Decaens, T. ^{[7
]}

Heurgue-Berlot, A. ^{[8
]}

Martin, A. O. ^{[9
]}

Paik, S. W. ^{[10
]}

Poulart, V. ^{[11
]}

Sehbai, A. S. ^{[12
]}

Takemura, N. ^{[13
]}

Yoon, J-H. ^{[14
]}

机构：

[1] Bristol Myers Squibb, Clin Dev Oncol, Princeton, NJ USA

[2] Emory Univ, Dept Hematol & Med Oncol, Winship Canc Inst, Atlanta, GA 30322 USA

[3] Hosp Univ Reina Sofia, Gastroenterol, Cordoba, Spain

[4] CHU Montpellier, Med Oncol, Hosp St Eloi, Montpellie, France

[5] Tulane Univ, Internal Med, Tulane Med Ctr, Hlth Sci Ctr, New Orleans, LA 70118 USA

[6] Calif Pacific, Med Ctr, San Francisco, CA USA

[7] CHU Grenoble Alpes, Clin Univ Hepatogastroenterol, Grenoble, France

[8] CHU Reims, Dept Hepatogastroenterol, Reims, France

[9] UAM, Digest Syst Serv, Hosp Univ La Paz, Madrid, Spain

[10] Sungkyunkwan Univ, Samsung Med Ctr, Gastroenterol, Seoul, South Korea

[11] Bristol Myers Squibb, Biostat, Braine Lalleud, Belgium

[12] Pinnacle Res Grp Llc, Hematol Oncol, Anniston, AL USA

[13] Tokyo Natl Ctr Global Hlth & Med, Gastroenterol Surg, Tokyo, Japan

[14] Seoul Natl Univ Hosp, Gastroenterol, Seoul, South Korea

来源：

ANNALS OF ONCOLOGY | 2018年 / 29卷

关键词：

D O I：

暂无

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

783TiP

引用

页数：2

共 50 条

[21] Adjuvant Therapy of Renal Cell Carcinoma with high Risk of Recurrence after Nephrectomy A randomized, multicentre, Placebo-controlled, double-blind Phase III Study of Atezolizumab (Anti-PD-L1 Antibody) as adjuvant Therapy for Patients with Renal Cell Carcinoma and a high Recurrence Risk after Nephrectomy (IMmotion010) - AN 42/16 of AUO
Rexer, H.
Doehn, C.
Gruellich, C.
UROLOGE, 2018, 57 (05): : 643 - 644
[22] A randomized, double-blind, placebo-controlled phase II study of adjuvant pembrolizumab versus placebo in patients with head and neck squamous cell cancers at high risk for recurrence: The PATHWay study.
Pearson, Alexander T.
Seiwert, Tanguy Y.
Cohen, Roger B.
Saba, Nabil F.
Kaczmar, John M.
Fidler, Mary J.
Wade, James L., III
Castellucci, Enrico
Karrison, Theodore
Katipally, Rohan Reddy
Juloori, Aditya
Rosenberg, Ari Joseph
Haraf, Daniel J.
Agrawal, Nishant
Vokes, Everett E.
JOURNAL OF CLINICAL ONCOLOGY, 2024, 42 (16)
[23] SEARCH: A Phase III, Randomized, Double-Blind, Placebo-Controlled Trial of Sorafenib Plus Erlotinib in Patients With Advanced Hepatocellular Carcinoma
Zhu, Andrew X.
Rosmorduc, Olivier
Evans, T. R. Jeffry
Ross, Paul J.
Santoro, Armando
Carrilho, Flair Jose
Bruix, Jordi
Qin, Shukui
Thuluvath, Paul J.
Llovet, Josep M.
Leberre, Marie-Aude
Jensen, Markus
Meinhardt, Gerold
Kang, Yoon-Koo
JOURNAL OF CLINICAL ONCOLOGY, 2015, 33 (06) : 559 - 566
[24] SUNITINIB TREATMENT OF RENAL ADJUVANT CANCER (S-TRAC): A RANDOMIZED, DOUBLE-BLIND, PHASE III STUDY OF SUNITINIB VS. PLACEBO IN SUBJECTS AT HIGH RISK OF RECURRENT RENAL CELL CARCINOMA (RCC)
Ravaud, A.
Motzer, R. J.
Pandha, H.
Staehler, M.
George, D. J.
Pantuck, A.
Patel, A.
Gerletti, P.
Chen, L.
Patard, J.
ANNALS OF ONCOLOGY, 2012, 23 : 292 - 293
[25] IMbrave050: Phase 3 study of adjuvant atezolizumab plus bevacizumab versus active surveillance in patients with hepatocellular carcinoma (HCC) at high risk of disease recurrence following resection or ablation
Trojan, J.
Chow, P.
Chen, M.
Cheng, A-L
Kaseb, A.
Kudo, M.
Lee, H. C.
Yopp, A.
Zhou, J.
Wang, L.
Wen, X.
Heo, J.
Tak, W-Y
Nakamura, S.
Numata, K.
Uguen, T.
Hsieh, D.
Cha, E.
Hack, S. P.
Lian, Q.
Spahn, J.
Wu, C.
Qin, S.
ONCOLOGY RESEARCH AND TREATMENT, 2023, 46 : 239 - 239
[26] ATLAS study: A randomized double-blind phase 3 study of adjuvant axitinib versus placebo in subjects at high risk of recurrent renal cell carcinoma (RCC).
Kwon, Tae Gyun
Seong, Seo
Byun, Seok-Soo
Miyake, Hideaki
Ueda, Takeshi
Ye, Dingwei
Garcia-Donas, Jesus
Gross-Goupll, Marine
Hutson, Thomas E.
DeBenedetto, Robert
Hariharan, Subramanian
Lee, Min Young
Linke, Rolf Gerhard
Tsuji, Fumito
Quinn, David I.
JOURNAL OF CLINICAL ONCOLOGY, 2014, 32 (15)
[27] Adjuvant Nivolumab for Localized Renal Cell Carcinoma at High Risk of Recurrence After Nephrectomy: Part B of the Randomized, Placebo-Controlled, Phase III CheckMate 914 Trial
Motzer, Robert J.
Bex, Axel
Russo, Paul
Tomita, Yoshihiko
Cutuli, Hernan Javier
Rojas, Carlos
Gross-Goupil, Marine
Schinzari, Giovanni
Melichar, Bohuslav
Barthelemy, Philippe
Ruiz Garcia, Abraham
Sosman, Jeffrey
Grimm, Marc-Oliver
Goh, Jeffrey C.
Suarez, Cristina
Kollmannsberger, Christian K.
Nair, Suresh G.
Shuch, Brian M.
Huang, Jian
Simsek, Burcin
Spiridigliozzi, Julia
Lee, Chung-Wei
van Kooten Losio, Maximiliano
Gruenwald, Viktor
JOURNAL OF CLINICAL ONCOLOGY, 2025, 43 (02) : 189 - 200
[28] A phase 3, randomized, double-blind, multicenter, placebo-controlled study of S-588410, a five-peptide cancer vaccine as an adjuvant therapy after curative resection in patients with esophageal squamous cell carcinoma
Makino, Tomoki
Miyata, Hiroshi
Yasuda, Takushi
Kitagawa, Yuko
Muro, Kei
Park, Jae-Hyun
Hikichi, Tetsuro
Hasegawa, Takahiro
Igarashi, Kenji
Iguchi, Motofumi
Masaoka, Yasuhide
Yano, Masahiko
Doki, Yuichiro
ESOPHAGUS, 2024, 21 (04) : 447 - 455
[29] Adjuvant ipilimumab versus placebo after complete resection of high-risk stage III melanoma (EORTC 18071): a randomised, double-blind, phase 3 trial
Eggermont, Alexander M. M.
Chiarion-Sileni, Vanna
Grob, Jean-Jacques
Dummer, Reinhard
Wolchok, Jedd D.
Schmidt, Henrik
Hamid, Omid
Robert, Caroline
Ascierto, Paolo A.
Richards, Jon M.
Lebbe, Celeste
Ferraresi, Virginia
Smylie, Michael
Weber, Jeffrey S.
Maio, Michele
Konto, Cyril
Hoos, Axel
de Pril, Veerle
Gurunath, Ravichandra Karra
de Schaetzen, Gaetan
Suciu, Stefan
Testori, Alessandro
LANCET ONCOLOGY, 2015, 16 (05) : 522 - 530
[30] A phase III study of atezolizumab (atezo) vs placebo as adjuvant therapy in renal cell carcinoma (RCC) patients (pts) at high risk of recurrence following resection (IMmotion010)
Uzzo, Robert
Bex, Axel
Rini, Brian I.
Albiges, Laurence
Suarez, Cristina
Donaldson, Frank
Asakawa, Takashi
Schiff, Christina
Pal, Sumanta K.
JOURNAL OF CLINICAL ONCOLOGY, 2017, 35

← 1 2 3 4 5 →